Celgene's Abraxane recommended by Scottish Medicines Consortium

10 February 2015

The Scottish Medicines Consortium has decided to recommend National Health Service use of Abraxane (paclitaxel) in combination with gemcitabine for the treatment of metastatic adenocarcinoma of the pancreas.

Abraxane is manufactured by US biotech company Celgene Corp (Nasdaq: CELG), and remains on NHS England’s Cancer Drugs Fund list until a final decision is made on its review.

Jeff Evans, professor of translational cancer research at the University of Glasgow, said: “I welcome the Scottish Medicine Consortium decision to approve the prescribing of Abraxane in Scotland. Pancreatic cancer has extremely low survival rates as the majority of patients are diagnosed at an advanced stage. Abraxane has shown that it is able to increase survival for patients with metastatic pancreatic cancer and now sufferers of the disease in Scotland will be able to benefit from this treatment.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK